Clariant focuses on core products with sale of pharmaceutical business
03/07/2006
After fulfilment of the local transfer requirements and approval of all relevant authorities, Swiss specialty chemical company Clariant completed the sale of its Pharmaceutical Fine Chemicals unit to TowerBrook Capital Partners, L.P. on June 30, for CHF110 million ($89.7 million).
Share this story:
